精准医学与肥胖
Precision Medicine and Obesity.
机构信息
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic Health System, 700 West Ave South, La Crosse, WI 54601, USA; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: https://twitter.com/MDanielaHurtado.
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.
出版信息
Gastroenterol Clin North Am. 2021 Mar;50(1):127-139. doi: 10.1016/j.gtc.2020.10.005. Epub 2021 Jan 5.
Abstract
The highly variable response to obesity therapies justifies the search for treatment strategies that are best suited to individual patients to enhance their effectiveness and tolerability via precision medicine. Precision medicine development in recent years has been driven by the emergence of powerful methods to characterize patients ("omic" assays). Current available information has revealed that there are numerous intermediary processes that contribute to obesity and have provided a framework for partially comprehending the mechanisms behind the heterogeneity of obesity and its clinical consequences. Some of these processes have or are currently being targeted to individualize obesity therapy with some success.
摘要
肥胖症治疗方法的高度差异性使得人们有理由去寻找个体化的治疗策略，通过精准医学来提高治疗效果和耐受性。近年来，精准医学的发展受到了用于对患者进行特征描述的强大方法（“组学”检测）的推动。目前已有的信息表明，有许多中间过程有助于肥胖症的形成，并为部分理解肥胖症及其临床后果的异质性背后的机制提供了一个框架。其中一些过程已经或正在被作为靶点，以实现肥胖症治疗的个体化，并且已经取得了一定的成功。
相似文献
1
Precision Medicine and Obesity.精准医学与肥胖
Gastroenterol Clin North Am. 2021 Mar;50(1):127-139. doi: 10.1016/j.gtc.2020.10.005. Epub 2021 Jan 5.
2
Nutrigenetics/Nutrigenomics, Personalized Nutrition, and Precision Healthcare.营养遗传学/营养基因组学、个性化营养和精准医疗。
Curr Nutr Rep. 2020 Dec;9(4):338-345. doi: 10.1007/s13668-020-00327-z.
3
Guide and Position of the International Society of Nutrigenetics/Nutrigenomics on Personalised Nutrition: Part 1 - Fields of Precision Nutrition.国际营养基因学/营养基因组学学会关于个性化营养的指南与立场：第1部分 - 精准营养领域
J Nutrigenet Nutrigenomics. 2016;9(1):12-27. doi: 10.1159/000445350. Epub 2016 May 12.
4
Precision Nutrition 4.0: A Big Data and Ethics Foresight Analysis--Convergence of Agrigenomics, Nutrigenomics, Nutriproteomics, and Nutrimetabolomics.精准营养4.0：大数据与伦理前瞻性分析——农业基因组学、营养基因组学、营养蛋白质组学和营养代谢组学的融合
OMICS. 2016 Feb;20(2):69-75. doi: 10.1089/omi.2015.0193. Epub 2016 Jan 19.
5
Nutrigenetics and nutrigenomics: ready for clinical use or still a way to go?营养遗传学与营养基因组学：已准备好用于临床应用，还是仍有很长的路要走？
Per Med. 2020 May 1;17(3):171-173. doi: 10.2217/pme-2020-0007. Epub 2020 Apr 24.
6
THE PRESENT AND FUTURE OF PERSONALIZED NUTRITION.个性化营养的现状与未来。
Rev Invest Clin. 2021;73(5):321-325. doi: 10.24875/RIC.21000346.
7
Future challenges and present ethical considerations in the use of personalized nutrition based on genetic advice.基于基因建议的个性化营养应用中的未来挑战与当前伦理考量
J Acad Nutr Diet. 2013 Nov;113(11):1447-1454. doi: 10.1016/j.jand.2013.05.028. Epub 2013 Aug 2.
8
Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches.精准肥胖治疗包括遗传药理学和营养遗传学方法。
Trends Pharmacol Sci. 2016 Jul;37(7):575-593. doi: 10.1016/j.tips.2016.04.008. Epub 2016 May 25.
9
Personalized nutrition for dementia prevention.针对痴呆症的个性化营养。
Alzheimers Dement. 2022 Jul;18(7):1424-1437. doi: 10.1002/alz.12486. Epub 2021 Nov 10.
10
Precision (Personalized) Nutrition: Understanding Metabolic Heterogeneity.精准（个性化）营养：理解代谢异质性。
Annu Rev Food Sci Technol. 2020 Mar 25;11:71-92. doi: 10.1146/annurev-food-032519-051736. Epub 2020 Jan 13.
引用本文的文献
1
Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?肥胖症的药物治疗：我们是否准备好选择、定制和联合药物治疗以实现更宏伟的目标？
Front Endocrinol (Lausanne). 2025 Jun 18;16:1569468. doi: 10.3389/fendo.2025.1569468. eCollection 2025.
2
Unraveling the Genetic Architecture of Obesity: A Path to Personalized Medicine.解析肥胖的遗传结构：通往个性化医疗之路。
Diagnostics (Basel). 2025 Jun 11;15(12):1482. doi: 10.3390/diagnostics15121482.
3
Body Composition and Its Outcomes and Management in Multiple Sclerosis: Narrative Review.多发性硬化症的身体成分及其后果与管理：叙述性综述
Nutrients. 2025 Mar 14;17(6):1021. doi: 10.3390/nu17061021.
4
The Spanish GIRO Guideline: A Paradigm Shift in the Management of Obesity in Adults.西班牙GIRO指南：成人肥胖管理的范式转变。
Obes Facts. 2025 Mar 29:1-13. doi: 10.1159/000544880.
5
Adult obesity treatment and prevention: A trans-agency commentary on the research landscape, gaps, and future opportunities.成人肥胖症的治疗与预防：跨部门对研究现状、差距及未来机遇的评论
Obes Rev. 2024 Sep;25(9):e13769. doi: 10.1111/obr.13769. Epub 2024 Jun 3.
6
The melanocortin-4 receptor pathway and the emergence of precision medicine in obesity management.黑素皮质素 4 受体途径与肥胖管理中精准医学的出现。
Diabetes Obes Metab. 2024 Apr;26 Suppl 2(Suppl 2):46-63. doi: 10.1111/dom.15555. Epub 2024 Mar 19.
7
Weight-centric prevention of cancer.以体重为中心的癌症预防。
Obes Pillars. 2024 Mar 5;10:100106. doi: 10.1016/j.obpill.2024.100106. eCollection 2024 Jun.
8
Exploring Genetic Testing for Rare Disorders of Obesity: Experience and Perspectives of Pediatric Weight Management Providers.探索肥胖罕见疾病的基因检测：儿科体重管理提供者的经验和观点。
Child Obes. 2024 Oct;20(7):451-458. doi: 10.1089/chi.2023.0125. Epub 2024 Jan 8.
9
Clinical review: Guide to pharmacological management in pediatric obesity medicine.临床综述：儿童肥胖医学药理学管理指南
Obes Pillars. 2023 Apr 27;6:100066. doi: 10.1016/j.obpill.2023.100066. eCollection 2023 Jun.
10
Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet: A Retrospective Matched Cohort Study.基于无麸质饮食的乳糜泻患者使用抗肥胖药物的疗效：一项回顾性匹配队列研究。
J Clin Gastroenterol. 2024 Aug 1;58(7):650-655. doi: 10.1097/MCG.0000000000001931.
本文引用的文献
1
A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements.肠道菌群在肥胖中的作用及益生菌补充剂的抗肥胖特性研究进展
Biomed Res Int. 2019 May 9;2019:3291367. doi: 10.1155/2019/3291367. eCollection 2019.
2
Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies.我们是否即将定义人类肥胖的代谢组学特征？代谢组学研究的系统评价。
Metabolomics. 2019 Jun 13;15(6):93. doi: 10.1007/s11306-019-1553-y.
3
Genetics and epigenetics in obesity.肥胖的遗传学和表观遗传学。
Metabolism. 2019 Mar;92:37-50. doi: 10.1016/j.metabol.2018.10.007. Epub 2018 Nov 3.
4
Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk.肥胖症患者的代谢组发生深刻变化，与健康风险相关。
Cell Metab. 2019 Feb 5;29(2):488-500.e2. doi: 10.1016/j.cmet.2018.09.022. Epub 2018 Oct 11.
5
Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients.与癫痫患者丙戊酸诱导肥胖相关的过氧化物酶体增殖物激活受体 γ（PPARγ）和分化群 36（CD36）多态性。
Psychopharmacology (Berl). 2018 Sep;235(9):2665-2673. doi: 10.1007/s00213-018-4960-2. Epub 2018 Jul 8.
6
Exercise training alters the genomic response to acute exercise in human adipose tissue.运动训练改变了人类脂肪组织对急性运动的基因组反应。
Epigenomics. 2018 Aug;10(8):1033-1050. doi: 10.2217/epi-2018-0039. Epub 2018 Apr 19.
7
Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial.低脂饮食与低碳水化合物饮食对超重成年人12个月体重减轻的影响以及与基因型模式或胰岛素分泌的关联：DIETFITS随机临床试验
JAMA. 2018 Feb 20;319(7):667-679. doi: 10.1001/jama.2018.0245.
8
Genetics of Obesity in Consanguineous Populations: Toward Precision Medicine and the Discovery of Novel Obesity Genes.同血缘人群肥胖的遗传学研究：迈向精准医学和新型肥胖基因的发现。
Obesity (Silver Spring). 2018 Mar;26(3):474-484. doi: 10.1002/oby.22064.
9
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.MC4R 缺乏症中黑皮质素-4 受体（MC4R）激动剂（Setmelanotide）的评估。
Mol Metab. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015. Epub 2017 Jul 8.
10
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.利拉鲁肽对肥胖患者体重、饱腹感和胃功能的影响：一项随机、安慰剂对照的初步试验。
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):890-899. doi: 10.1016/S2468-1253(17)30285-6. Epub 2017 Sep 27.
Zotero 插件